NorthCrest Asset Manangement LLC Sells 527 Shares of GSK plc (NYSE:GSK)

NorthCrest Asset Manangement LLC trimmed its holdings in GSK plc (NYSE:GSK) by 0.1% in the fourth quarter, Holdings Channel reports. The fund owned 383,061 shares of the pharmaceutical company’s stock after selling 527 shares during the period. NorthCrest Asset Manangement LLC’s holdings in GSK were worth $12,955,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of GSK. FMR LLC increased its holdings in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after buying an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC raised its position in GSK by 14.3% in the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after buying an additional 51,378 shares during the last quarter. Cerity Partners LLC lifted its stake in GSK by 61.8% in the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after acquiring an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC boosted its position in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after acquiring an additional 83,433 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on GSK shares. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Sunday, January 5th. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Performance

NYSE:GSK traded down $0.52 during mid-day trading on Friday, hitting $33.23. The stock had a trading volume of 1,397,186 shares, compared to its average volume of 2,548,916. The company’s 50 day simple moving average is $34.46 and its 200 day simple moving average is $38.24. The stock has a market cap of $68.87 billion, a price-to-earnings ratio of 21.58, a PEG ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were paid a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.73%. The ex-dividend date was Friday, November 15th. GSK’s payout ratio is currently 98.70%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.